Erythroid-Specific Transcriptional Changes in PBMCs from Pulmonary Hypertension Patients by Cheadle, Chris et al.
Erythroid-Specific Transcriptional Changes in PBMCs
from Pulmonary Hypertension Patients
Chris Cheadle
1*, Alan E. Berger
1, Stephen C. Mathai
2, Dmitry N. Grigoryev
3, Tonya N. Watkins
1,
Yumiko Sugawara
1, Sangjucta Barkataki
1, Jinshui Fan
1, Meher Boorgula
1, Laura Hummers
4,
Ari L. Zaiman
2, Reda Girgis
2, Michael A. McDevitt
5, Roger A. Johns
6, Frederick Wigley
4,
Kathleen C. Barnes
1, Paul M. Hassoun
2*
1Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 2Division of Pulmonary/
Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 3Medical Genetic Core, Children’s Mercy Hospitals
and Clinics, Kansas City, Missouri, United States of America, 4Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
of America, 5Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 6Department of Anesthesiology and
Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
Abstract
Background: Gene expression profiling of peripheral blood mononuclear cells (PBMCs) is a powerful tool for the
identification of surrogate markers involved in disease processes. The hypothesis tested in this study was that chronic
exposure of PBMCs to a hypertensive environment in remodeled pulmonary vessels would be reflected by specific
transcriptional changes in these cells.
Methodology/Principal Findings: The transcript profiles of PBMCs from 30 idiopathic pulmonary arterial hypertension
patients (IPAH), 19 patients with systemic sclerosis without pulmonary hypertension (SSc), 42 scleroderma-associated
pulmonary arterial hypertensio patients (SSc-PAH), and 8 patients with SSc complicated by interstitial lung disease and
pulmonary hypertension (SSc-PH-ILD) were compared to the gene expression profiles of PBMCs from 41 healthy individuals.
Multiple gene expression signatures were identified which could distinguish various disease groups from controls. One of
these signatures, specific for erythrocyte maturation, is enriched specifically in patients with PH. This association was
validated in multiple published datasets. The erythropoiesis signature was strongly correlated with hemodynamic measures
of increasing disease severity in IPAH patients. No significant correlation of the same type was noted for SSc-PAH patients,
this despite a clear signature enrichment within this group overall. These findings suggest an association of the
erythropoiesis signature in PBMCs from patients with PH with a variable presentation among different subtypes of disease.
Conclusions/Significance: In PH, the expansion of immature red blood cell precursors may constitute a response to the
increasingly hypoxic conditions prevalent in this syndrome. A correlation of this erythrocyte signature with more severe
hypertension cases may provide an important biomarker of disease progression.
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Introduction
Pulmonary arterial hypertension (PAH) is a vascular disease that
carries significant morbidity and mortality [1,2,3]. Morbidity and
mortality rates vary and depend on the age, the degree of
pulmonary hypertension, and the response to vasodilator therapy.
Death as a result of both acute and chronic right heart failure may
occur. PAH is currently characterized by uncontrolled cell
proliferation and inflammation involving the pulmonary vascular
resistive vessels, leading to a progressive increase in pulmonary
vascular resistance, right ventricle hypertrophy, and eventual heart
failure.
PAH can complicate connective tissue diseases such as
scleroderma [4,5] as well as other autoimmune diseases such as
systemic lupus erythematosus and rheumatoid arthritis [6,7].
Scleroderma, or systemic sclerosis (SSc), is a chronic multisystem
autoimmune disease characterized by a vasculopathy, diffuse
fibrosis of skin and various internal organs, and immune
abnormalities. Up to 10–15% of SSc patients eventually develop
PAH [8]. While the factors which lead a subset of SSc patients to
go on to develop PAH are unclear, it is of great clinical interest to
develop early markers of SSc-associated PAH (SSc-PAH) disease
in order to provide more aggressive treatment to the ‘‘at risk’’
patient population. The early phase of the disease process has been
difficult to study rigorously because of the delay in the diagnosis of
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34951SSc-PAH and the lack of reliable biomarkers for early disease.
Lung biopsy is avoided since it is invasive and unsafe in these
patients. For this reason we chose to use gene expression profiling
of peripheral blood mononuclear cells (PBMCs) as a surrogate
tissue which is readily obtainable from patients and provides a large
pool of gene transcripts shown to have the potential to be highly
sensitive to the disease microenvironments on a systems wide basis
[9,10]. Previous studies using PBMCs have demonstrated an
ability to discriminate between PAH, in general, and healthy
controls, identify PAH-specific genes [11], as well as distinguish
between IPAH and SSc-PAH gene signatures [12]. However,
more recent studies have shown considerable heterogeneity when
examining directly the contrast in gene expression profiles in
PBMCs from SSc-PAH and SSc patients [13,14,15]. For example,
while Pendergrass et al. [13] focused on the increased expression
of 9 genes that distinguished SSc-PAH from SSc, Risbano et al.
[14] describe 5 genes which when down-regulated distinguish SSc-
PAH from SSc patients. We hypothesized that chronic exposure of
PBMCs to elevated pulmonary pressures in remodeled pulmonary
vessels will be reflected by specific transcriptional changes in these
cells and distinguish PH of various etiologies from both SSc and
normal controls.
Results
Expression Profiling
The transcript profiles of PBMCs from 42 SSc associated PAH
(SSc-PAH) patients, 30 IPAH patients, 19 patients with SSc, and 8
patients with SSc complicated by interstitial lung disease and PH
(SSc-PH-ILD) were compared to the transcript profiles of PBMCs
from 41 healthy individuals (see Table 1 for a summary of
demographic and clinical patient descriptions, see Table S3 for all
relevant clinical data and descriptions, on a patient-by-patient
basis). In our initial data analysis we compared the gene expression
for each disease group versus that of the controls (as described in
Methods) and found large numbers of significantly regulated genes
between patients and controls (Figure 1). Among the 89 genes
significantly up-regulated in common among IPAH and SSc with
or without accompanying PH were components of the Toll-like
receptor (TLR) signaling pathway including the STAT1, TLR7,
and TLR8 genes. An expanded search of all genes in the TLR
signaling pathway revealed a broad general trend (Figure 2A) of
up-regulation of these genes in each disease group (ttest p-values of
the average expression of these pathway genes by group versus
controls were p=0.04 for IPAH, p=0.0006 for SSc-PAH, and
p=0.004 for SSc, SSc-PH-ILD was not significant at p=0.09)
altogether suggesting a chronic activation of the innate immune
system in these patients. Scleroderma patients with or without
PAH demonstrated a pattern of 30 distinct immune response
genes (DAVID [NIH Database for Annotation, Visualization, and
Integrated Discovery]: defense response; p,7610
24) up-regulated
in common including CXCL10, FCGR1A, HCK, MX2, NCF1C,
PARP4, and TLR4 (see Table S1 for all cited genes, enrichment
results, and complete group comparison results).
Interestingly, PH patients (IPAH and SSc-PAH) shared a large
number of distinct genes (118) (Figure 1A) that were significantly
up-regulated in these PH groups but not in SSc including a total of
seven genes CA2, HBA2, HBD, HBG1, HBG2, HBM, HBQ1
shown to be highly enriched for blood gas transport (DAVID: gas
transport: p,7610
210). This same group of 118 genes also
contained a sub-group of genes involved in platelet biology
(DAVID: platelet alpha granule: p,16
26), a finding seen as well
using MsigDB (Broad Institute Molecular Signatures Data Base)
(platelet specific genes: p,1.66
212).
The 136 genes down-regulated for all disease groups relative to
healthy controls were significantly enriched for apoptosis (DAVID:
apoptosis: p,1.46
24), a trend that extended to the additional 170
down-regulated genes in common between SSc-PAH and IPAH
(DAVID: regulation of apoptosis: p,3.06
26). Further examina-
tion of down-regulated changes in gene expression individually in
each condition using the methods of gene set analysis (webPAGE
[16]) revealed a common trend of down-regulation of multiple
pathways involved in T cell function (Table 2). Examination of
several of these pathways in detail (Figure 2B) demonstrated a clear
pattern of down-regulation of genes in these pathways across all
patient groups relative to controls.
Signature Identification
Unsupervised clustering of 296 genes (chosen from a pool of the
500 most variable genes and which displayed distinct clustering
patterns) across all samples shows a clear trend of multiple clusters
of correlated gene expression (Figure 3). Many of these clusters
overlap the groups noted above. For example, in the first cluster,
Immune Response genes down-regulated (IR-DR), 56 of the 58
genes depicted in this cluster are members of the group of the
statistically down-regulated genes shared by all three major disease
groups (IPAH, SSc-PAH, and SSc). Conversely, over half of the
genes (41/81) in the Immune Response genes up-regulated (IR-
UR) cluster are members of the group of the statistically up-
regulated genes shared by all three major disease groups (IPAH,
SSc-PAH, and SSc). Additional clusters included a gene expres-
sion signature originally identified in neutrophils [17] and found as
an immature neutrophil signature (INS) in the PBMC fraction of
blood from both vasculitis related to Wegener’s granulomatosis
[18] and systemic lupus erythematosus [19] patients relative to
healthy controls, presumably as part of an aggravated chronic
immune response. In this study the INS signature, when present,
appears to be distributed nonspecifically among all samples.
Although these three signatures (IR-UR, IR-DR, and INS) were
clearly identified and annotated they were of less interest to this
study either because of their general non-specificity (INS) or
because of their inability to distinguish among separate disease
groups (IR-UR, IR-DR). Two other signatures, however, both of
which had been identified by functional annotation during our
initial analysis (the gas transport and platelet specific genes), were
represented by clusters shown here also to be related. The average
expression levels for the Illumina probes in these two distinct
groups have a Pearson correlation r=0.6 across all subjects (see
Table S2 for a complete listing of the genes in these two clusters).
A distinctive feature of the gene expression of these two signatures
(Erythroid Differentiation Signature – EDS; and Platelet derived –
Pl) is that they are specific primarily to disease groups of patients
with PH studied in this cohort (IPAH, SSc-PAH, SSc-PH-ILD).
Signature Characterization
In order to further characterize disease specific gene expression,
all patient and control samples (see Methods) were directly
evaluated by the methods of gene set analysis using gene lists
derived from the Mouse Genome Informatics (MGI) database
[20]. The file used for mouse phenotypic information contains
5011 distinct genes and 5142 phenotypic terms derived from
information from specific gene mutations in multiple mouse
strains, including an extensive library of specific gene knock-in and
knock-out strains. In this analysis, patterns of gene expression
among the PH, control and SSc groups were visualized across the
entirety of the dataset by displaying the average gene expression
for every mouse gene set for each human sample (Figure 4A).
Patterns of disease specific gene set expression were detected
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Variable Overall (n=140) Control (n=41) SSc (n=19) IPAH (n=30) SSc-PAH (n=42) SSc-PH-ILD (n=8)
Age (mean 6 SD years) 53613 45612 55610 52612 60613 61611
Gender n (%)
Female 117 (83.6) 34 (82.9) 19 (100) 25 (83.3) 33 (78.6) 6 (75.0)
Male 23 (16.4) 7 (17.0) 0 (0) 5 (16.7) 9 (21.4) 2 (25.0)
Race n (%)
African American 20 (14.3) 7 (17.1) 0 (0) 5 (16.7) 8 (19.0) 0 (0)
Asian 4 (2.9) 1 (2.4) 0 (0) 1 (3.3) 1 (2.4) 1 (12.5)
Caucasian 115 (82.1) 33 (80.5) 19 (100) 23 (76.7) 33 (78.6) 7 (87.5)
Hispanic 1 (0.7) 0 (0) 0 (0) 1 (3.3) 0 (0) 0 (0)
NYHA functional class n (% of the
PAH subjects)
I 9 (11.3) NA NA 7 (23.3) 2 (4.8) 0 (0)
II 39 (48.7) NA NA 16 (53.3) 22 (52.4) 1 (12.5)
III 30 (37.5) NA NA 6 (20.0) 17 (40.4) 7 (87.5)
IV 2 (2.5) NA NA 1 (3.3) 1 (2.4) 0 (0)
NA (# for which value is not available) 60 (the non-PAH
subjects)
41 19 0 0 0
6MWD (mean 6 SD (# missing values)) 11746395 (64) NA NA 13836392 (3) 10916340 (1) 8916378 (0)
RA mean (mean 6 SD (# missing
values))
7.764.2 (61) NA NA 7.764.2 (0) 7.964.4 (1) 7.563.8 (0)
CI (mean 6 SD (# missing
values))
2.6660.72 (61) NA NA 2.6160.69 (0) 2.6660.74 (1) 2.8860.80 (0)
PVRI (mean 6 SD (# missing
values))
10626573 (61) NA NA 12146573 (0) 9556556 (1) 10426610 (0)
PA saturation (mean 6 SD (# missing
values))
66.768.2 (65) NA NA 66.169.1 (2) 67.168.0 (2) 66.966.7 (1)
Except where indicated otherwise, values are the number (%).
doi:10.1371/journal.pone.0034951.t001
Figure 1. Venn diagrams illustrating the distribution of statistically significant disease-specific changes in gene expression. A) up-
regulated and B) down-regulated gene expression for comparisons between SSc, SSc-PAH, and IPAH patients versus healthy controls. Total number
of calculated differentially expressed genes for each comparison are as indicated below each diagram.
doi:10.1371/journal.pone.0034951.g001
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of blood disorders (Figure 4A, as indicated by arrows in the right
panel). A summary of the differential expression p-value scores for
these six blood disorder pathways when the individual disease
groups were compared to controls shows a marked elevation of
gene expression in the SSc-PH-ILD, IPAH, and SSc-PAH groups
but not for SSc patients (Figure 4B). In particular, the contrast
between SSc-PAH and SSc patients is striking.
The combination of elevated hemoglobin gene expression in
patients with PH and the preliminary evidence that many
Figure 2. Heat map illustration of the distribution of gene expression among all samples for genes selected by pathways. A) TLR
(Toll-like Receptor) Signaling, B) TCR (T cell receptor) Pathway, Ca
2+/NFAT Signaling. Red indicates increase and green indicates decrease in relative
gene expression for each gene calculated individually across all samples.
doi:10.1371/journal.pone.0034951.g002
Table 2. Gene Set Analysis – selected pathway results illustrate a strong downward regulation of the adaptive immune response
across multiple pathways for all disease groups versus healthy controls regardless of patient diagnosis.
GeneSet Annotation IPAH_v_Control SSc-PH-ILD_v_Control SSc-PAH_v_Control SSc_v_Control
TOB1 PATHWAY BioCarta 24.620 24.205 25.096 26.653
CA
2+NFAT SIGNALING GEArray 25.695 23.866 25.047 25.395
IL12 PATHWAY BioCarta 23.757 23.740 24.826 26.919
TCR PATHWAY BioCarta 24.963 24.673 25.085 24.813
CCR5 PATHWAY BioCarta 24.488 23.189 25.027 25.916
ARE/NRF2 PATHWAY BioCarta 24.174 22.190 24.210 25.027
IL2PATHWAY BioCarta 23.685 23.575 22.811 23.572
TH1-TH2-TH3 GENES SABiosciences 23.263 23.289 21.938 24.736
Enrichment scores are derived using the PAGE technique (see Methods) and are equivalent to (gene set size adjusted) Gaussian distributed z scores. The negative sign
direction of the scores indicates that for each of the indicated pathways and comparisons the average gene expression is lower in the disease group than in controls.
Shaded pathways (Ca2+NFAT signaling and the TCR Pathway) are broken out on a gene by gene and sample by sample basis in Figure 2.
doi:10.1371/journal.pone.0034951.t002
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gene set analysis to mouse blood disorder phenotypes suggested
that human PH patients may be distinguished from healthy
controls and SSc patients by a programmatic shift in gene
expression in PBMCs, perhaps related to conditions of tissue
hypoxia such as induced by PH. In order to further explore the
functional implications of these regulated gene groups, a compre-
hensive list of genes was derived for the EDS and for the Pl groups
by selecting all microarray probes in the complete dataset whose
expression levels have a Pearson Correlation $0.7 with the
average expression for the probes in each cluster (EDS; 42
Illumina probes, 40 unique genes, and Pl; 60 probes, 54 unique
genes) as initially shown in Figure 3, across all the samples. This
resulted in the identification of 169 Illumina probes representing
149 unique genes for the EDS, and 456 probes covering 384
unique genes for the Pl signatures, respectively (Table S2). These
are the sets of probes and genes used for further analysis of these
signatures.
Tissue specificity of the EDS
The full gene list for the EDS signature (149 unique genes) was
next tested against the Gene Expression Barcode, a web-based tool
[21] which allows for highly accurate estimates of tissue specific
gene expression. Inspection of the EDS gene expression across
a catalog of over 130 curated human tissue types derived from the
GEO (Gene Expression Omnibus) and the ArrayExpress public
repositories demonstrated that the expression of EDS genes as
a group is highly restricted to a few distinctive cell types (Figure 5)
of the hematopoietic lineage including a very high level of
enrichment in reticulocytes and in bone marrow. Reticulocytes
from cord blood were particularly enriched relative to reticulocytes
from circulation. It is interesting to note in this context that cord
blood has been well characterized as having a less mature
reticulocyte population than adult blood [22].
Inspection of the EDS specific gene list showed markedly
increased levels of expression for two genes in particular, ALAS2
(aminolevulinate, delta-, synthase2) (Illumina Probe ID [ILMN
2367126]) and ERAF (erythroid differentiation associated factor;
recently renamed to AHSP [alpha hemoglobin stabilizing protein])
(Illumina Probe ID [ILMN 1696512]), (Figure 6 A&B) both
essential for the terminal differentiation of erythroid cells [23]. The
specific overexpression of ALAS2 and ERAF in hypertension
samples was confirmed by RT-PCR (Figure 6C). The expression
levels of these two genes track so well with the EDS gene
expression signature overall (Pearson’s correlation coefficient of
r=0.92 for ERAF and r=0.95 for ALAS2 versus the average
EDS gene expression across all samples) that we are using them as
single gene candidate biomarkers to track EDS-specific gene
expression elevation in patients currently enrolled in ongoing
longitudinal studies. The tissue specific expression of both of these
genes is restricted, primarily to fetal liver, bone marrow (in adults),
and most abundantly in CD71+ early erythroid cells in the
circulation (BioGPS http://biogps.gnf.org). We note that hemo-
globin production in erythroid cells is one of the most important
stages in their terminal differentiation [24], the induction of
ALAS2 is essential for hemoglobin production [25] and ERAF/
AHSP is essential for proper assembly of nascent alpha globin
incorporation into hemoglobin-A [26]. In addition, conditions of
hypoxia have been shown to directly result in elevated levels of
ALAS2 in a human model of erythroid terminal differentiation
[27].
External Validation of the Association of the EDS with
Pulmonary Hypertension
In order to examine the extent of EDS association with PH, in
general, beyond this current study, a survey was carried out of
other published PH microarray studies (with and without SSc) in
which PBMCs were the target tissue and for which full datasets
were available through GEO (NCBI – Gene Expression Omnibus)
[31]. A total of four datasets were identified, three of them recently
published (in 2010), each of which contained at least one
phenotype for PH (Table 3). Two of these datasets also included
phenotypes for SSc both with and without accompanying PH
(Risbano et al. [14] and Pendergrass et al. [13]). Each dataset was
queried using the methods of gene set analysis using the EDS gene
expression signature gene list embedded in a background of over
550 pathway gene lists derived from multiple sources. The
strongest overall enrichment scores for the EDS were, not
surprisingly, generated from the PH phenotypes of our own study
(JHU; SSc-PH-ILD-33.3, IPAH-21.1, and SSc-PAH-17.9). The
slightly positive enrichment score for the JHU SSc group reflects
several patients who are EDS positive (and who may be
progressing towards PH).
Figure 3. Heat map of unsupervised clustering (genes only) of
296 genes selected for both high variance (from a set of 500
most variant genes) and also as representative of six major
patterns of distinctly correlated genes across the dataset. These
patterns included an Immune Response signature (up- or down-
regulated between controls and disease: IR-UR and IR-DR, respectively),
the Erythroid Differentiation Signature (EDS) a Platelet specific signature
(Pl), and an Immature Neutrophil Signature (INS). The gender specific
cluster acts as a positive control, the specific signatures are discussed in
detail in the text, particularly that of the EDS.
doi:10.1371/journal.pone.0034951.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34951Figure 4. Results from gene set analysis of all gene expression data versus gene lists derived from the Mouse Genome Informatics
(MGI) database. A) Gene set enrichment scores were calculated by the PAGE method using row normalized data for all (filtered) genes and samples.
The scores were averaged by group and are normalized in the sense that that the average gene expression as scored by PAGE for any one gene set is
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significantly enriched for the EDS signature relative to controls
and other non-PH phenotypes. In many cases the EDS gene list
was the top scorer above all other pathways and signatures. In
Risbano et al. [14] IPAH and SSc-PAH had scores of 26 and 7.6,
respectively, while the SSc phenotype showed a strong negative
enrichment of -15.5. An explanation for this anomaly can be seen
by a sample by sample analysis using the gene expression of both
ALAS2 and ERAF/AHSP as surrogate EDS biomarkers (Fig-
ure S1). In the Risbano et al. study [14], for reasons unclear, the
EDS is suppressed in SSc patients relative to controls, while both
the IPAH and the SSc-PAH groups contain patients with elevated
biomarker levels relative to either controls or SSc groups.
Conversely, in Pendergrass et al [13], patients with a diagnosis
of SSc-PAH are clearly enriched for the EDS (PAGE enrichment
score =15) but so also, albeit to a lesser degree, are patients
diagnosed with SSc (PAGE enrichment score =9.25). A possible
explanation for this, once again, becomes clear upon the
examination of gene expression sample by sample (Figure S1).
In the Pendergrass data at least three patients scored as SSc have
a high EDS score perhaps indicating, as within our own cohort,
a further, as yet undetected, progression to the PH state. In
datasets examining only PH (Bull et al. [11] and Rajkumar et al.
[32] there is a clear and unambiguous enrichment (Table 3. Bull et
al.; IPAH-7.7 and Rajkumar et al.; PAH-4.1, respectively) in their
PH groups relative to controls. In the Rajkumar data, patients with
idiopathic pulmonary fibrosis (IPF), a lung disease group not
associated with PH did not display the EDS.
Interestingly, the platelet specific signature (Pl), while distinct in
terms of gene content from the EDS (less than 5% gene overlap),
was present in some patients with high EDS (Figure 3, Table S2),
but did not show as much specificity for hypertension in our study
or others (Figure S2) and for this reason was not pursued further.
An additional data set was also evaluated which compared the
gene expression between reticulocytes from cord blood and in the
circulation [33]. The EDS was highly over-expressed in cord
blood reticulocytes relative to peripheral blood supporting pre-
vious observations characterizing the presence of a less mature
reticulocyte population in cord blood [22,33] and supporting the
identification of the EDS with reticulocyte development.
Correlation of the EDS with Hemodynamic
Measurements
It should be noted that despite the strong association of the EDS
signature with the PH phenotype in our data and in others, only
a subset of the patients in each group actually display elevated
EDS levels. In order to better understand the association of EDS
positive patients with disease progression, EDS gene expression
regulation was examined for those patients for whom hemody-
namic measurements were available within four months of the
date of blood draw for the PBMC isolations used in this study (12
IPAH; 23 SSc-PAH). The clinical parameters of mean right atrial
pressure (RAmean), cardiac index (CI), pulmonary vascular
resistance index (PVRI), and pulmonary artery saturation (PA
sat) were used. ALAS2 gene expression was taken as a primary
biomarker representing the entire EDS (note the Pearson
correlation r between ALAS2 and ERAF/AHSP gene expression,
among the subjects used for this analysis, was 0.987, and 0.957 for
expressed as the z transformation ((gene set size adjusted) of the average gene expression for that set. Disease specific patterns of gene set
enrichment are as shown in the zoomed image. B) Average gene set expression in disease groups versus controls for various blood disorder-specific
gene sets (as indicated by arrows in Fig. 4A) were tested by Students t test, the results being reported as the negative log (base 10) of the derived p-
value (2 log(p)).
doi:10.1371/journal.pone.0034951.g004
Figure 5. Gene Expression Barcode for EDS signature genes.
The heat map is derived from individual barcode scores from zero
(black) to one (red) with red indicating an increased likelihood that the
gene is present in all samples in the experiment from which the tissue
specific expression estimate is derived (see McCall et al. for complete
description of the barcode algorithm [21]). As shown, the genes for the
EDS signature were overrepresented for three tissues, in particular (cord
blood reticulocytes, adult blood reticulocytes, and bone marrow), and
their respective number of barcode expression calls are as indicated in
the barchart directly below the corresponding areas of the barcode
heatmap.
doi:10.1371/journal.pone.0034951.g005
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34951Figure 6. Statistically significant differential expression of erythroid CD71+ specific genes. A) ALAS2 and B) ERAF/AHSP genes in
hypertension groups (SSc-PH-ILD, IPAH, and SSc-PAH) versus healthy controls and scleroderma (SSc). The box plots give the mean (horizontal black
line), sample values (short blue lines), and 84% confidence interval (CI) (red lines) for each group, (non-overlap of the 84% CIs of two groups is an
Pulmonary Hypertension Signature in PBMC
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purpose of computing correlations of the EDS with hemodynamic
measurements (Figure 8). Disease severity in IPAH patients as
indicated by increasing RAmean and PVRI were strongly
correlated with increasing ALAS2 gene expression (r=0.776,
p=0.003; r=0.752, p=0.0048, respectively). Conversely, mea-
sures of healthy lung and cardiac function such as PA saturation
and Cardiac Index (CI) were negatively correlated with decreasing
ALAS2 gene expression (r=20.71, p=0.0098; r=20.449,
p=0.14, respectively). The consistency of these measurements
suggests that there is indeed a direct correlation between disease
severity and EDS gene expression in IPAH patients. Surprisingly,
there were no corresponding significant correlations for any of
these four hemodynamic parameters among the SSc-PAH patients
(Figure S3) despite the clear and significant enrichment for EDS
genes (see Figure 6A&B) in this group. The level of EDS gene
over-expression among SSc-PAH patients was thus not seen to be
directly related to the markers of PH disease status examined here
and distinguishes IPAH and SSc-PAH for that reason.
Discussion
Previous studies using PBMC have been used to identify PH-
specific genes [11] as well as distinguishing between IPAH and
SSc-PAH [12]. In general, however, these studies have shown
considerable heterogeneity when examining directly the contrast
in gene expression profiles in PBMC from SSc-PAH and SSc
patients [13,14]. For example, while Pendergrass et al. [13]
focused on the increased expression of 9 genes that distinguished
SSc-PAH from SSc, Risbano et al. [14] described 5 genes which
when down-regulated distinguish SSc-PAH from SSc patients. In
a comparison of the complete datasets from these studies in
combination with results from this current study we found one
gene, in particular, ALAS2, which is significantly over-expressed
in SSc-PAH versus SSc in all three datasets. We present data here
in support of the finding that one of the distinguishing molecular
phenotypes in terms of gene expression between patients with
PAH versus either healthy controls or patients with SSc alone,
involves a distinctive signature uniquely associated with erythro-
cyte development. This signature was also present in patients with
IPAH and SSc-PH-ILD in the current study and segregates with
PH in multiple published clinical studies for which data is publicly
available [11,13,14,32]. We have demonstrated here that the EDS
signature is quantitatively enriched and validated in at least four
independently published datasets derived from microarray studies
across multiple microarray platforms (Affymetrix, Illumina, and
Agilent) in which the PBMCs from PH patients were tested.
In all cases (our data and others) only a subset of PH patients in
the affected groups were EDS positive and in our data, at least, the
presence of the EDS was associated with increasingly severe
disease (as judged by hemodynamic parameters) for IPAH but not
for SSc-PAH patients (Figure 8, Figure S3). The presence of the
EDS signature induced by PAH may be indicative of increased red
blood cell recruitment as part of a systemic response to severe
chronic local hypoxia. An increase of up-regulated genes
selectively expressed in erythrocytes/reticulocytes (including
ALAS2 and ERAF/AHSP, and many other EDS genes) in whole
blood was also noted to be consistent with previous observations of
higher red blood cell counts (hematocrit) in obesity [34]. An
increase in RBC trafficking may constitute a useful marker of PH
disease, in general, and serve as a useful marker of increased
disease severity specifically in IPAH patients. The lack of
correlation of the EDS genes with hemodynamic measurements
in the SSc-PAH patients is puzzling, particularly, as the signature
as a whole is similarly enriched in patients from both disease
groups. This perhaps reflects the different etiologies of these two
different types of PH and emphasizes their distinct origins.
Furthermore, we have previously reported that hemodynamic
alterations are distinct between IPAH and SSc-PAH patients and
do not always reflect, in the latter group, the severity of PAH
[35,36].
The cell specific source of the EDS remains an open question.
In order to eliminate the likelihood that direct RBC contamination
in the PBMC preparations used in this current study might
account for the presence of the EDS, PBMC samples from both
high and low EDS patients were subjected to multiple rounds of
isotonic ammonium chloride hemolysis. This treatment lyses
mature red blood cells with minimal effect on lymphocytes and
does not appreciably affect nucleated red cells. In our test samples
high EDS gene expression was not affected by this treatment
(Figure S4).
High levels of gene expression for ALAS2 and ERAF are found
almost exclusively in CD71+ erythroid progenitor cells, and the
complete EDS signature (as defined here) appears to correlate
especially well with genes known to be expressed in reticulocytes
and particularly well in cell populations enriched for less mature
reticulocytes (as in cord blood – Figure 5). Our hypothesis is that
the EDS gene expression signature is derived from a population of
nucleated reticulocytes which co-sediment with lymphocytes and
monocytes in the PBMC fraction of Ficoll gradients.
The identity of the EDS corresponds closely to a gene
expression signature reported by Ebert et al., [37] where the
authors provide detailed gene expression information for an in
vitro experiment in which bone marrow CD34+ cells were
expanded under conditions which induced erythroid differentia-
tion and major changes in gene expression were recorded pre- and
post- induction. Our EDS gene list overlapped the induced
erythroid gene list by over 50% including both the ALAS2 and
ERAF genes (ALAS2, CA1, EPB42, ERAF, FECH, GLRX5,
GSPT1, GYPB, GYPE, HBA2, MYL4, SELENBP1, SLC25A37,
SNCA, TMCC2, and TSPAN5). Interestingly, a major difference
between the Ebert induced erythroid signature and the PAH EDS
is the very strong upregulation of IL8 recorded in the Ebert
approximate indicator of significant difference between their means at the 0.05 level of significance). C) Individual ALAS2 and ERAF gene expression
microarray results were validated by RT-PCR for high and low EDS patients across all hypertension classes (SSc-PAH, IPAH, SSc-PH-ILD).
Further inspection of the EDS gene list also showed the inclusion of genes for both the GATA1 and KLF transcription factors which are both essential
for erythroid development [28,29]. A test by gene set analysis of the entire dataset comparing each PH group directly versus the SSc group as the
baseline group showed a significant and specific enrichment among genes which contain three different GATA transcription factor binding sites in
their upstream promoter regions (TRANSFAC [30]) (Figure 7A). Interestingly, the genes up-regulated in each of the GATA transcription factor binding
site gene sets were mostly non-overlapping either with each other (an average of 59–62% unique genes for each gene list) or with the EDS gene
expression signature itself (95% unique non-overlapping genes) (Figure 7B) indicating that the effects of elevated GATA1 gene expression are both
pervasive in the PH groups and are supplemental to the EDS gene expression signature itself. The observation that downstream regulatory events are
related directly to EDS elevation (through the up-regulation of the GATA1 transcription factor gene) and are associated with PH groups, taken
together with the previously demonstrated strong association of the EDS with reticulocyte maturation (Figure 5), led us to the identification of this
signature as the Erythroid Development Signature (EDS).
doi:10.1371/journal.pone.0034951.g006
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34951Figure 7. Results from gene set analysis using gene lists derived from the TransFac (gene associated transcription factor binding
sites) database. A). The average changes in gene expression for patients with SSc-PH-ILD, IPAH, and SSc-PAH were tested versus patients with SSc.
The p-values associated with the gene set enrichment scores are reported here as 2log(p). B). Venn diagram illustrating overlap between the average
up-regulated gene expression associated with the presence of 3 distinct GATA transcription factor binding sites. The EDS gene signature is included
for comparison.
doi:10.1371/journal.pone.0034951.g007
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sporadically and non-specifically across the entire PAH dataset).
The reason for this discrepancy is not clear but worth noting given
the otherwise very strong correlation between the two signatures.
Additional evidence for the source of the EDS in PBMCs has
recently been obtained indirectly by others. Researchers from the
Children’s Hospital in Cincinnati reported the up-regulation of the
expression of genes involved in the processes of hemoglobin
synthesis and oxygen transport in the PBMCs of systemic juvenile
idiopathic arthritis (sJIA) patients relative to healthy controls [38].
They suggested (as we do here) that this cluster of genes might
represent the signature of immature nucleated RBCs that can
copurify with PBMCs isolated on Ficoll gradients. The PH and the
sJIA erythropoiesis signatures are highly overlapping (Figure S5)
suggesting a common PBMC cell source. The Cincinnati team
also mapped their experimentally derived EDS using bioinfor-
Table 3. Results from gene set analysis using the EDS as the query gene list. Enrichment scores are as described above.
Dataset GEO # SSc-PH-ILD IPAH SSc-PAH SSc PAH IPF-PH CBvAB
JHU GSE33463 33.327 21.082 17.886 2.688 - - -
Risbano et al.
14 GSE22356 - 26.019 7.553 215.476 - - -
Pendergrass et al.
13 GSE19617 - - 15.004 9.247 - - -
Bull et al.
11 GSE703 - 7.736 - - - - -
Rajkumar et al.
31 GSE15197 - - - - 4.083 21.337 -
Goh et al.
32 GSE6236 - - - - - - 7.811
In all cases data was downloaded from the NCBI Gene Expression Omnibus (GEO) website as processed by the submitter and published by GEO as a Series Matrix File.
Phenotype labels: Interstitial Lung Disease (SSC-PH-ILD), Idiopathic Arterial Hypertension (IPAH), Scleroderma with Pulmonary Arterial Hypertension (SSc-PAH),
Scleroderma (SSc), Pulmonary Arterial Hypertension only (PAH), Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension (IPF-PH), and human Cord Blood versus
human Adult Blood (CBvAB).
doi:10.1371/journal.pone.0034951.t003
Figure 8. ALAS2 gene expression positively correlates with increasing disease severity in IPAH patients. EDS gene expression for 12
IPAH patients for whom hemodynamic measurements were available within four months of the date of blood draw. The clinical parameters of right
atrial pressure (RAmean), cardiac index (CI), pulmonary vascular resistance index (PVRI), and pulmonary artery saturation (PA sat) were used. Disease
severity in IPAH patients as indicated by increasing RAmean and PVRI are strongly correlated with increasing ALAS2 gene expression and negatively
correlated with measures of healthy lung and coronary function such as PA saturation and Cardiac Index (CI).
doi:10.1371/journal.pone.0034951.g008
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and, in addition, they present data showing that patients with sJIA
had significantly increased proportions of immature cell popula-
tions, including CD34+ cells, correlating highly with the strength
of their measurements of the erythropoiesis signature. It has been
independently demonstrated by in vitro expansion experiments that
the potential, at least, for the production of large amounts of
erythroid progenitor cells can be derived directly from PBMCs
without additional purification [40], although whether the source
of this expansion is derived from CD34+ cells remains uncertain
[41]. Despite the strong indirect evidence presented by ourselves
and others, the direct evidence for the expansion of CD71+
erythrocyte precursors in the periphery as the source of the EDS
remains to be demonstrated.
The exact role of the EDS in specific disease states remains to be
determined. Clearly there are strong associations between the EDS
and PH and sJIA, but also the EDS has been observed in active
lupus as well, and co-segregates with multiple additional immune-
related signatures in a large asthma cohort study (unpublished
data). In an ongoing longitudinal PAH study that we are currently
conducting, it has become clear that the EDS as well as the
immune response and platelet signatures are also variable in
patients over time. Unfortunately, it is still too early for more than
a speculative interpretation of these results. For now, it would
appear that the EDS is an important new marker in chronic
disease with the distinct property that in hypertension, at least, the
expansion of immature precursor cells may actually constitute an
active biological response to increasingly severe disease conditions.
Materials and Methods
Ethics Statement
All the samples used during this study were obtained following
written informed consent from the donors. The Johns Hopkins
University Institutional Review Board approved the conduct of
this study.
Study subjects
The cohort was comprised of subjects identified from the Johns
Hopkins Pulmonary Hypertension Program and the Johns
Hopkins Scleroderma Center as part of our center’s Specialized
Center for Clinically-Oriented Research program. Consecutive
outpatients with a diagnosis of IPAH, SSc-PAH, SSc-PH-ILD and
SSc were recruited and enrolled in the study between 2007 and
2010. Controls subjects were family and friends who accompanied
subjects to clinic visits and had no known cardiovascular,
pulmonary, or renal disease.
Limited or diffuse SSc was as previously defined [42]. PAH was
defined as a mean pulmonary artery pressure (mPAP) of
.25 mmHg, pulmonary artery wedge pressure (PAWP)
#15 mmHg, and pulmonary vascular resistance (PVR) .3 Wood
units [43], in the absence of other known causes of pulmonary
hypertension. Results of pulmonary function tests (PFT) and high-
resolution computed tomography (HRCT) of the chest closest to
the date of the diagnostic RHC (right heart catheterization) were
recorded. Percent of predicted results for all PFT data were
calculated according to Crapo [44]. Patients with significant
obstructive lung disease, defined as a forced expiratory volume in
one second over forced vital capacity ratio (FEV1/FVC) ,0.5 or
0.5–0.7 accompanied by radiographic evidence of emphysema,
were excluded [45,46]. Interstitial lung disease was defined by
a combination of PFT and HRCT criteria as previously described
in epidemiologic studies and clinical trials of PAH therapy
[47,48,49]. Patients were classified as having SSc-PH-ILD if they
met all the above criteria, and had a total lung capacity (TLC) of
,60% of predicted or a TLC between 60% and 70% of predicted
combined with moderate to severe fibrosis (grade 3–4) on HRCT
[50]. The onset of scleroderma was defined by the first non-
Raynaud’s phenomenon manifestation.
Severity of PAH was assessed by routine functional and
hemodynamic measurements obtained closest to the date of blood
collection for genomic analyses. Subjects were then stratified by
cardiac index dichotomized at 2.2 L/min/m
2 based upon prior
studies demonstrating poorer survival for PAH patients with a CI
less than this value [51].
Isolation of Peripheral Blood Mononuclear Cells
Venous blood was collected by simple venipuncture under
aseptic conditions. All samples were processed within two hours of
collection to minimize gene expression variations associated with
longer sample incubation times [52]. PBMCs were separated by
Ficoll density gradient, immediately lysed in Trizol reagent
(Invitrogen, Carlsbad, California), and stored at 280uC.
Purification of RNA
Total RNA was extracted using the Trizol Reagent method
(Invitrogen, Carlsbad, California 92008, cat. no. 15596-026).
Additional purification was performed on RNeasy columns
(Qiagen, Valencia, CA 913555, cat. no. 74104). The quality of
total RNA samples was assessed using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA).
Microarray Analysis
RNA samples were labeled according to the chip manufac-
turer’s recommended protocols. In brief, for Illumina, 0.5 mgo f
total RNA from each sample was labeled by using the Illumina
TotalPrep RNA Amplification Kit (Ambion, Austin, TX 78744-
1832, cat. no. IL1791) in a two step process of cDNA synthesis
followed by in vitro RNA transcription. Single stranded RNA
(cRNA) was generated and labeled by incorporating biotin-16-
UTP. 0.75 ugs of biotin-labeled cRNA was hybridized (16 hours)
to Illumina Sentrix Human HT12_v3 BeadChips (Illumina, San
Diego, CA 92121-1975, cat.no. BD-103-0203). The hybridized
biotinylated cRNA was detected with streptavidin-Cy3 and
quantitated using Illumina’s BeadStation 500GX Genetic Analysis
Systems scanner. The expression data discussed in this publication
have been deposited in NCBI’s Gene Expression Omnibus [53]
and are accessible through GEO Series accession number GSE
33463 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE 33463).
Quantitative RT-PCR (QRT-PCR) Analysis
cDNA was obtained from total RNA using the cDNA Archive
Kit according to the manufacturer’s protocol (Applied Biosystems,
Foster City, CA). Probes and primers were designed and
synthesized by Applied Biosystems. All PCR amplifications were
carried out in triplicate on an ABI PrismH 7300 Sequence
Detection System, using a fluorogenic 59 nuclease assay (Taq-
ManH probes). Relative gene expressions were calculated by using
the 2
2DDCt method as described in [54]. The DCt value of each
sample was calculated using 3 endogenous control genes
(GAPDH, ACTB, and PGK1).
Analytical Methods and Statistical Analysis
A single intensity (expression) value for each Illumina probe on
the array was obtained using Illumina BeadStudio software with
standard settings and no background correction. The expression
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median 256 (2
8) and then log (base 2) transformed before
performing statistical analysis. Analysis for differential expression
between pairs of disease groups and between individual disease
groups and the group of controls was carried out for each Illumina
microarray probe.
Illumina probes (and consequently, the corresponding genes)
considered to be significantly differentially expressed between two
groups of samples were those satisfying the three criteria: (i) Two-
sided Welch t-test p-values less than or equal to 0.01 [55]; (ii)
a Benjamini-Hochberg false discovery rate (FDR) less than or
equal to 0.1 [56]; and (iii) a fold change above 1.5 or below 1/1.5
(calculated using geometric means). Statistical testing for differ-
ences in expression levels of a given probe between two groups was
not done unless at least 80% of the samples in the group with the
higher average expression level for that probe had Illumina
detection p-values ,0.01 (thus avoiding false positives based on
background noise and also reducing the number of statistical tests
for the subsequent false discovery rate calculation). A comprehen-
sive spreadsheet of group comparison results is given in Table S1.
Heat maps (and the ordering by hierarchical clustering of the
samples and the genes in heat maps) were based on normalization
of the expression values for each sample using z transformation
[55,57,58] (utilizing only the probes which had an Illumina
detection p-value ,0.01 for least one sample, and for which there
was an available gene symbol), followed by z-transformation of the
normalized expression values for each Illumina probe across all
samples. Hierarchical clustering was performed using the Cluster
and TreeView software programs [59]. The clustering algorithm
was set to complete linkage clustering using uncentered correla-
tion.
Gene set analysis was carried out using the web-PAGE tool [16]
(http://dpwebpage.nia.nih.gov/PAGE/index.html) with the p-
value cutoff set to 0.01 and the minimum number of genes per
gene set equal to 10. The input used was either a z ratio (z
transformation of the difference between the means computed for
two groups [60] (Table 2, Table 3-JHU data, Figure 7) for all
internal data; or a simple difference metric was computed and
used for all external data (Table 2). One exception was the use of
all row normalized data on a sample by sample basis to generate
the functional genomic landscape as illustrated in Figure 4A. In
this variation of the gene set algorithm, gene sets are tested against
the complete expression data for each sample, enrichment scores
map the relative abundance levels of groups of genes which can
then be compared for variation between samples and groups of
samples as seen. The gene sets used are as described in the
corresponding Table and Figure legends.
Evaluation of lists of differentially expressed genes for
enrichment in predefined categories and functional groups of
genes was carried out using the NIH functional analysis tool
DAVID [61], and the Broad Institute Molecular Signatures
Database MSigDB facility [62].
Associating hemodynamic measurements with gene
expression
Correlation between expression levels of a given gene and the
values of a selected clinical variable for a specified group of n
subjects was evaluated as the Pearson product-moment correlation
coefficient r estimating the population correlation coefficient r.
Tests of the null hypothesis r=0 were conducted using the
customary t-test depending on r and n.
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Table S1 PAH significance tests, gender specific EDS
stats, siglists-unique, UR functional enrichment, DR
functional enrichment.
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Table S2 EDS and Platelet specific genes.
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Figure S1 EDS genes in published PH gene expression
datasets.
(TIF)
Figure S2 Platelet signature in published PH gene
expression datasets.
(TIF)
Figure S3 Correlations of ALAS2 gene expression with
clinical measurements in SSc-PAH patients.
(TIF)
Figure S4 RBC lysis treatment shows no effect on EDS
gene expression.
(TIF)
Figure S5 EDS genes over-expressed in sJIA dataset.
(TIF)
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